SG11202109839YA - Lipocalin mutein for treatment of asthma - Google Patents

Lipocalin mutein for treatment of asthma

Info

Publication number
SG11202109839YA
SG11202109839YA SG11202109839YA SG11202109839YA SG 11202109839Y A SG11202109839Y A SG 11202109839YA SG 11202109839Y A SG11202109839Y A SG 11202109839YA SG 11202109839Y A SG11202109839Y A SG 11202109839YA
Authority
SG
Singapore
Prior art keywords
asthma
treatment
lipocalin mutein
lipocalin
mutein
Prior art date
Application number
Other languages
English (en)
Inventor
Lena Therese Axelsson
David Robert Close
Philip Gardiner
Aulikki Ingergard Alexandra Jauhianinen
Ekaterina Pardali
Mary Fitzgerald
Gabriele Matschiner
Ingmar Bruns
Gunnel Marita Olsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG11202109839YA publication Critical patent/SG11202109839YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
SG11202109839Y 2019-03-29 2020-03-25 Lipocalin mutein for treatment of asthma SG11202109839YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962826791P 2019-03-29 2019-03-29
US201962845774P 2019-05-09 2019-05-09
US201962906443P 2019-09-26 2019-09-26
PCT/EP2020/058360 WO2020200960A1 (en) 2019-03-29 2020-03-25 Lipocalin mutein for treatment of asthma

Publications (1)

Publication Number Publication Date
SG11202109839YA true SG11202109839YA (en) 2021-10-28

Family

ID=70008540

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109839Y SG11202109839YA (en) 2019-03-29 2020-03-25 Lipocalin mutein for treatment of asthma

Country Status (11)

Country Link
US (1) US20220193191A1 (ja)
EP (1) EP3946415A1 (ja)
JP (1) JP2022526524A (ja)
KR (1) KR20210146934A (ja)
CN (1) CN113613669A (ja)
AU (1) AU2020252050A1 (ja)
CA (1) CA3133422A1 (ja)
IL (1) IL286756A (ja)
MA (1) MA55490A (ja)
SG (1) SG11202109839YA (ja)
WO (1) WO2020200960A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022129629A1 (en) 2020-12-18 2022-06-23 Astrazeneca Ab Lipocalin mutein dry powder formulation for treatment of asthma
CN114780621B (zh) * 2022-06-23 2022-10-04 中铁电气化勘测设计研究院有限公司 一种轨道交通接触网缺陷检索方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
EP1430136A1 (en) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
CA2659413C (en) 2006-08-01 2016-06-14 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
CN105949301B (zh) 2010-06-08 2020-03-27 皮里斯制药有限公司 结合IL-4受体α的泪脂质运载蛋白突变蛋白
DK3453400T3 (da) 2011-12-13 2021-04-06 Pieris Pharmaceuticals Gmbh Fremgangsmåder til forebyggelse eller behandling af visse forstyrrelser ved inhibering af binding af il-4 og/eller il-13 til deres respektive receptorer

Also Published As

Publication number Publication date
CN113613669A (zh) 2021-11-05
WO2020200960A1 (en) 2020-10-08
US20220193191A1 (en) 2022-06-23
AU2020252050A1 (en) 2021-11-11
CA3133422A1 (en) 2020-10-08
EP3946415A1 (en) 2022-02-09
MA55490A (fr) 2022-02-09
IL286756A (en) 2021-10-31
KR20210146934A (ko) 2021-12-06
JP2022526524A (ja) 2022-05-25

Similar Documents

Publication Publication Date Title
IL292810A (en) Therapeutic compounds and methods of use
IL286756A (en) Lipocalin mutein for treatment of asthma
IL287796A (en) Preparations and methods for the treatment of diseases mediated by ATPase
GB201910803D0 (en) USe of cannabidol in treatment of dravet syndrome
EP3735209A4 (en) TREATMENT OF THE PROGRESSION OF MYOPOIA
EP3981453A4 (en) Fan of ventilator for use in treatment
IL292657A (en) Therapeutic history of interleukin-22
ZA202207493B (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
EP3927428A4 (en) METHODS OF TREATMENT OF RESPIRATORY CONDITIONS
IL278978A (en) Preparations and methods for treating eczema
GB201918404D0 (en) Compounds and their use for the treatment of aplha1-antitrypsin deficiency
GB201918413D0 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918414D0 (en) Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB201916428D0 (en) Treatment of hydro-carbon-contaminated materials
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
GB2589398B (en) Compounds and methods of use
EP3987032A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
SG10201902000YA (en) Isthmin 1 for treatment of lung inflammation
GB201907305D0 (en) Treatment of conditions
IL290983A (en) Treatment methods
GB201918853D0 (en) Methods of treatment
EP4037689A4 (en) 18-MC FOR THE TREATMENT OF SUBSTANCE USE DISORDERS
GB201900942D0 (en) Methods of treatment
GB201901130D0 (en) Formulation for the treatment of tendinopathies
EP4065573A4 (en) TREATMENT METHODS